<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613716</url>
  </required_header>
  <id_info>
    <org_study_id>115200</org_study_id>
    <nct_id>NCT01613716</nct_id>
  </id_info>
  <brief_title>Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)</brief_title>
  <acronym>OPERA</acronym>
  <official_title>Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the use of the dexamethasone implant (Ozurdex) in patients with
      macular edema associated with an epiretinal or preretinal membrane requiring surgical
      intervention. After the surgery is performed (pars plana vitrectomy), an Ozurdex implant will
      be placed in the eye. Patients will be followed for 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study to examine the use of Ozurdex in patients who are undergoing pars
      plana vitrectomy for macular edema due to preretinal membranes. Specifically, we will examine
      its effect on macular edema (measured by OCT), and visual recovery (measured by visual
      acuity). We will examine its use in patients who underwent pars plana vitrectomy for macular
      edema with associated taut membrane. This will be a prospective pilot study with patients to
      receive an Ozurdex implant at the time of vitrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Retinal Thickness</measure>
    <time_frame>3 months</time_frame>
    <description>At 3 months, central retinal thickness as measured by optical coherence tomography will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>ETDRS visual acuity will be measured at 3 months. Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard. A higher letter score represents better functioning.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Ozurdex injections and will be monitored for macular edema.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Ozurdex .7 mg injected into the treated eye</description>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are undergoing pars plana vitrectomy for:

               -  Epiretinal membrane/vitreomacular traction or

               -  Diabetic macular edema

          2. Patients with macular edema as measured by OCT (at least 250 um central subfoveal
             thickness)

          3. Informed consent requirements: All study subjects must agree to participate in the
             study and provide written informed consent, which will be written in English.

          4. Age between 18-85 years old

        Exclusion Criteria:

          1. Age &lt; 18 years or &gt; 85 years

          2. History of macular edema due to diseases other than those in the inclusion criteria in
             the study eye

               -  History of active inflammatory eye disease (uveitis) (within 3 months)

               -  History of ocular malignancy and/or ocular/orbital irradiation

               -  History of recent retinal vein occlusion (within 6 months)

               -  History of neovascular age-related macular degeneration or choroidal neovascular
                  membrane [

               -  History of juxtafoveal telangiectasia

               -  History of Coat's disease

               -  History central serous choroidoretinopathy

               -  History of previous infectious retinitis (toxoplasmosis, acute retinal necrosis,
                  tuberculosis, etc)

          3. Patients with a history of intraocular infection in the study eye (i.e. viral
             retinitis, endophthalmitis)

          4. Patients who are cognitively impaired or those who are unable to provide informed
             written consent

          5. Patients with a history of glaucoma in the study eye (defined as increased cup to disc
             ratio with associated nerve damage. Patients with ocular hypertension controlled by
             topical glaucoma drops (maximum 3) will not be excluded).

          6. Patient with recent intravitreal injections of steroids or anti-VEGF medications in
             the study eye (within past 4 weeks).

          7. Patients with recent periocular steroid injection (within past 4 weeks) in the study
             eye

          8. Patients on topical NSAIDS drops (patient will be eligible if they discontinue use of
             topical NSAIDs at time of study enrollment) in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Srivastava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cole Eye Institute, Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <results_first_submitted>March 12, 2018</results_first_submitted>
  <results_first_submitted_qc>April 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2018</results_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Sunil Srivastava</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Macular Edema</keyword>
  <keyword>Epiretinal Membrane</keyword>
  <keyword>Vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ozurdex</title>
          <description>Subjects will receive Ozurdex injections and will be monitored for macular edema.
Ozurdex: Ozurdex .7 mg injected into the treated eye</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screen failures</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ozurdex</title>
          <description>Subjects will receive Ozurdex injections and will be monitored for macular edema.
Ozurdex: Ozurdex .7 mg injected into the treated eye</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.63" lower_limit="37" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Central Retinal Thickness</title>
        <description>At 3 months, central retinal thickness as measured by optical coherence tomography will be measured</description>
        <time_frame>3 months</time_frame>
        <population>Optical Coherence Tomography was collected at 3 months. 22 of the patients were seen at month 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex</title>
            <description>Subjects will receive Ozurdex injections and will be monitored for macular edema.
Ozurdex: Ozurdex .7 mg injected into the treated eye</description>
          </group>
        </group_list>
        <measure>
          <title>Central Retinal Thickness</title>
          <description>At 3 months, central retinal thickness as measured by optical coherence tomography will be measured</description>
          <population>Optical Coherence Tomography was collected at 3 months. 22 of the patients were seen at month 3.</population>
          <units>micrometers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350" lower_limit="208" upper_limit="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>ETDRS visual acuity will be measured at 3 months. Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard. A higher letter score represents better functioning.</description>
        <time_frame>3 months</time_frame>
        <population>23 of the participants were able to come in for their 3 month appointment per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ozurdex</title>
            <description>Subjects will receive Ozurdex injections and will be monitored for macular edema.
Ozurdex: Ozurdex .7 mg injected into the treated eye</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>ETDRS visual acuity will be measured at 3 months. Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard. A higher letter score represents better functioning.</description>
          <population>23 of the participants were able to come in for their 3 month appointment per protocol</population>
          <units>ETDRS</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="0" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from point of screening until their last visit at 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ozurdex</title>
          <description>Subjects will receive Ozurdex injections and will be monitored for macular edema.
Ozurdex: Ozurdex .7 mg injected into the treated eye</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Patient subsequently underwent a CABG procedure, had a previous history of cardiac issues.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent Corneal Epithelial Defect</sub_title>
                <description>Patient had a persistent corneal defect after vitrectomy surgery and implantation of Ozurdex. Subsequently healed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Area of tractional retinal detachment versus retinoschisis surgery eye</sub_title>
                <description>Patient had an are of possible tractional retinal detachment versus retinoschisis noted throughout the surgery after vitrectomy surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ozurdex placment on fovea</sub_title>
                <description>After placement of Ozurdex it adhered to the fovea, requiring a second surgery where it went back into the normal position.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic ulcers-hospitalized for stomach pain</sub_title>
                <description>Patient had a bout of stomach and was hospitalized and diagnosed with peptic ulcers.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Root canal infection</sub_title>
                <description>Patient had a root canal and developed an infection afterwards</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Removal of basal cell carcinoma</sub_title>
                <description>Patient had a biopsy of the nose that was subsequently diagnosed as a basal cell carcinoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>found during a sleep study during a cardiology visit.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cartoid blockage</sub_title>
                <description>Patient had previous history of blockage was scheduled for outpatient stent</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in cataract surgical eye</sub_title>
                <description>Increase in cataract in the surgical eye</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increase in cataract fellow eye</sub_title>
                <description>Increase in cataract surgery fellow eye</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increase in intraocular pressure</sub_title>
                <description>Increase in intraocular pressure</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Worsening of diabetic disease fellow eye</sub_title>
                <description>Worsening of diabetic eye disease or cystoid macular edema</description>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>worsening of posterior capsular opacity</sub_title>
                <description>Worsening of posterior capsular opacity study eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>worsening of posterior capsular opacity fellow eye</sub_title>
                <description>As described above</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>increased cystoid macular edema study eye</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Epithelial defect study eye</sub_title>
                <description>Patient had reported epithelial defect after vitrectomy surgery.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased itching both eyes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increase in pain study eye</sub_title>
                <description>Patient noted increased pain in surgical eye</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased diabetic retinopathy study eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increase of dryness of the eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>loss of vision fellow eye</sub_title>
                <description>Patient reported decrease vision fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>small choroidal study eye</sub_title>
                <description>Choroidal was found postoperatively from vitrectomy surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage study eye</sub_title>
                <description>Patient had a vitreous hemorrhage of study eye</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Trouble reading</sub_title>
                <description>Patient reported difficulty with reading both eyes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Foreign body sensation of eyes</sub_title>
                <description>Patient reported feeling like something was in their eyes and irritating it- nothing was found in their eyes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Subconjunctival hemorrhage fellow eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased floaters fellow eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Decreased television vision fellow eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Glare with vision at night</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tearing in both eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Patient reported diarrhea, did not seek medical attention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Digestion issues</sub_title>
                <description>Patient had reported digestion issue later diagnosed with GERD</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope after injection</sub_title>
                <description>patient had syncope episode after protocol injection of ozurdex</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis Flare</sub_title>
                <description>Patient had a flare of previously diagnosed sarcoidosis</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental infection</sub_title>
                <description>Infection after dental procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <description>Reported sinus infections</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Motor vehicle accident</sub_title>
                <description>Patient was involved motor vehicle collusion no hospitalizations</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea, vomiting diarrhea,dehydration</sub_title>
                <description>Went to the emergency room the night of surgery with complications of anesthesia from vitrectomy surgery- was not admitted</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injury to hip an back</sub_title>
                <description>Patient had a work related injury requiring physical therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>broken patella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischemic Avent</sub_title>
                <description>Patient had history of previous TIAs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Worsening of Parkinson's tremors</sub_title>
                <description>Patient had past medical history of Parkinson's</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory flu</sub_title>
                <description>Respiratory flu</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Trouble breathing</sub_title>
                <description>patient was diagnosed with pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Poison Ivy rash</sub_title>
                <description>Was treated in the emergency room for poison ivy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sunil K. Srivastava, MD</name_or_title>
      <organization>Cleveland Clinic Foundation</organization>
      <phone>216-636-2286</phone>
      <email>srivass2@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

